Molecular insights and therapeutic implications of nanoengineered dietary polyphenols for targeting lung carcinoma: part I

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71–96 (2008).
  MedlineGoogle Scholar
• 2. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–386 (2015).
  Medline CASGoogle Scholar
• 3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
  Medline CASGoogle Scholar
• 4. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med. 359(13), 1367–1380 (2008).
  Medline CASGoogle Scholar
• 5. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J. Clin. 50(1), 7–33 (2000).
  Medline CASGoogle Scholar
• 6. Das SS, Singh SK, Verma P, Jha NK, Gupta PK, Dua K. Mitigating inflammation using advanced drug delivery by targeting TNF-alpha in lung diseases. Future Med. Chem. 14(2), 57–60 (2021).
  MedlineGoogle Scholar
• 7. Yakut T, Schulten HJ, Demir A et al. Assessment of molecular events in squamous and non-squamous cell lung carcinoma. Lung Cancer 54(3), 293–301 (2006).
  MedlineGoogle Scholar
• 8. Pesch B, Kendzia B, Gustavsson P et al. Cigarette smoking and lung cancer – relative risk estimates for the major histological types from a pooled analysis of case–control studies. Int. J. Cancer 131(5), 1210–1219 (2012).
  Medline CASGoogle Scholar
• 9. Brenner DR, Boffetta P, Duell EJ et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am. J. Epidemiol. 176(7), 573–585 (2012).
  MedlineGoogle Scholar
• 10. Field RW, Withers BL. Occupational and environmental causes of lung cancer. Clin. Chest Med. 33(4), 681–703 (2012).
  MedlineGoogle Scholar
• 11. Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int. J. Epidemiol. 36(5), 1048–1059 (2007).
  MedlineGoogle Scholar
• 12. WHO. Diet, nutrition and the prevention of chronic diseases: report of a joint WHO/FAO expert consultation. In: Technical Report Series. World Health Organization. Geneva, Switzerland (2003).
  Google Scholar
• 13. Anand P, Kunnumakkara AB, Sundaram C et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res. 25(9), 2097–2116 (2008). •• Outlines the therapeutic approaches for targeting major signaling pathways in lung carcinogenesis.
  Medline CASGoogle Scholar
• 14. Bettio D, Venci A, Achille V, Alloisio M, Santoro A. Lung cancer in which the hypothesis of multi-step progression is confirmed by array-CGH results: a case report. Exp. Ther. Med. 11(1), 98–100 (2016).
  Medline CASGoogle Scholar
• 15. Blanco D, Vicent S, Fraga MF et al. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 9(10), 840–852 (2007).
  Medline CASGoogle Scholar
• 16. Zhou Q, Pan H, Li J. Molecular insights into potential contributions of natural polyphenols to lung cancer treatment. Cancers (Basel) 11(10), 1565 (2019).
  Medline CASGoogle Scholar
• 17. Hilbe W, Manegold C, Pircher A. Targeting angiogenesis in lung cancer – pitfalls in drug development. Transl. Lung Cancer Res. 1(2), 122–128 (2012).
  MedlineGoogle Scholar
• 18. McClelland MR, Carskadon SL, Zhao L et al. Diversity of the angiogenic phenotype in non-small-cell lung cancer. Am. J. Respir. Cell Mol. Biol. 36(3), 343–350 (2007).
  Medline CASGoogle Scholar
• 19. Lambert AW, Wong CK, Ozturk S et al. Tumor cell-derived periostin regulates cytokines that maintain breast cancer stem cells. Mol. Cancer Res. 14(1), 103–113 (2016).
  Medline CASGoogle Scholar
• 20. Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev. 35(1), 75–91 (2016).
  Medline CASGoogle Scholar
• 21. Das SS, Alkahtani S, Bharadwaj P et al. Molecular insights and novel approaches for targeting tumor metastasis. Int. J. Pharm. 585, 119556 (2020).
  Medline CASGoogle Scholar
• 22. Das SS, Verma PRP, Kar S, Singh SK. Quercetin-loaded nanomedicine as oncotherapy. In: Nanomedicine for Bioactives. Rahman MBeg SKumar VAhmad F (Eds). Springer Nature, Gateway East Singapore, Singapore, 155–183 (2020).
  Google Scholar
• 23. Barkat HA, Das SS, Barkat MA, Beg S, Hadi HA. Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. Future Oncol. 16(35), 2959–2979 (2020).
  CASGoogle Scholar
• 24. Buchner FL, Bueno-de-Mesquita HB, Linseisen J et al. Fruits and vegetables consumption and the risk of histological subtypes of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 21(3), 357–371 (2010).
  Medline CASGoogle Scholar
• 25. Das SS, Verma PRP, Singh SK. Quercetin-loaded nanomedicine as nutritional application. In: Nanomedicine for Bioactives. Rahman MBeg SKumar VAhmad F (Eds). Springer Nature, Gateway East Singapore, Singapore, 259–301 (2020).
  Google Scholar
• 26. Suvarna V, Chaubey P, Sangave PC, Singh AK. An insight of polyphenols in lung cancer chemoprevention. In: Polyphenols: Prevention and Treatment of Human Disease (2nd Edition). Watson RRPreedy VRZibadi S (Eds). Academic Press, Washington, DC, USA, 125–136 (2018).
  Google Scholar
• 27. Barkat HA, Barkat MA, Taleuzzaman M, Das SS, Rizwanullah M, Hadi HA. Receptor-based combinatorial nanomedicines. In: Handbook of Research on Advancements in Cancer Therapeutics. Kumar SRizvi MAVerma S (Eds). IGI Global, PA, USA, 339–355 (2021).
  Google Scholar
• 28. Christensen KY, Naidu A, Parent ME et al. The risk of lung cancer related to dietary intake of flavonoids. Nutr. Cancer 64(7), 964–974 (2012).
  Medline CASGoogle Scholar
• 29. Das SS, Hussain A, Verma PRP et al. Recent advances in liposomal drug delivery system of quercetin for cancer targeting: a mechanistic approach. Curr. Drug Deliv. 17(10), 845–860 (2020).
  Medline CASGoogle Scholar
• 30. Grosso G, Godos J, Lamuela-Raventos R et al. A comprehensive meta-analysis on dietary flavonoid and lignan intake and cancer risk: level of evidence and limitations. Mol. Nutr. Food Res. 61(4), 10.1002/mnfr.201600930 (2017). • Overview of various polyphenols (phenolic acids, stilbenes and lignans) in lung cancer therapy.
  MedlineGoogle Scholar
• 31. Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 16(13), e510–e521 (2015).
  Medline CASGoogle Scholar
• 32. Wegener G. Let food be thy medicine, and medicine be thy food: Hippocrates revisited. Acta Neuropsychiatr. 26(1), 1–3 (2014).
  MedlineGoogle Scholar
• 33. Valdés L, Cuervo A, Salazar N, Ruas-Madiedo P, Gueimonde M, González S. The relationship between phenolic compounds from diet and microbiota: impact on human health. Food Funct. 6(8), 2424–2439 (2015).
  Medline CASGoogle Scholar
• 34. Yue W, Ming QL, Lin B et al. Medicinal plant cell suspension cultures: pharmaceutical applications and high-yielding strategies for the desired secondary metabolites. Crit. Rev. Biotechnol. 36(2), 215–232 (2016).
  Medline CASGoogle Scholar
• 35. Farzaei M, Rahimi R, Abdollahi M. The role of dietary polyphenols in the management of inflammatory bowel disease. Curr. Pharm. Biotechnol. 16(3), 196–210 (2015).
  Medline CASGoogle Scholar
• 36. Rasouli H, Farzaei MH, Mansouri K, Mohammadzadeh S, Khodarahmi R. Plant cell cancer: may natural phenolic compounds prevent onset and development of plant cell malignancy? A literature review. Molecules 21(9), 1104 (2016).
  MedlineGoogle Scholar
• 37. Amararathna M, Johnston MR, Rupasinghe HPV. Plant polyphenols as chemopreventive agents for lung cancer. Int. J. Mol. Sci. 17(8), 1352 (2016).
  MedlineGoogle Scholar
• 38. El Gharras H. Polyphenols: food sources, properties and applications – a review. Int. J. Food Sci. Technol. 44(12), 2512–2518 (2009).
  Google Scholar
• 39. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 79(5), 727–747 (2004).
  Medline CASGoogle Scholar
• 40. Maleki Dana P, Sadoughi F, Asemi Z, Yousefi B. The role of polyphenols in overcoming cancer drug resistance: a comprehensive review. Cell. Mol. Biol. Lett. 27(1), 1 (2022).
  MedlineGoogle Scholar
• 41. Bhosale PB, Ha SE, Vetrivel P, Kim HH, Kim SM, Kim GS. Functions of polyphenols and its anticancer properties in biomedical research: a narrative review. Transl. Cancer Res. 9(12), 7619–7631 (2020).
  Medline CASGoogle Scholar
• 42. Zamora-Ros R, Rothwell JA, Scalbert A et al. Dietary intakes and food sources of phenolic acids in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br. J. Nutr. 110(8), 1500–1511 (2013).
  Medline CASGoogle Scholar
• 43. D’Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R. Polyphenols, dietary sources and bioavailability. Annali-Istituto Superiore di Sanita. 43(4), 348 (2007).
  MedlineGoogle Scholar
• 44. Jakobek L, Seruga M, Novak I, Medvidovic-Kosanovic M. Flavonols, phenolic acids and antioxidant activity of some red fruits. Deutsche Lebensmittel Rundschau 103(8), 369–377 (2007).
  CASGoogle Scholar
• 45. Mattila P, Pihlava J-M, Hellström J. Contents of phenolic acids, alkyl- and alkenylresorcinols, and avenanthramides in commercial grain products. J. Agric. Food Chem. 53(21), 8290–8295 (2005).
  Medline CASGoogle Scholar
• 46. Chrzanowski G, Leszczynski B, Czerniewicz P, Sytykiewicz H, Matok H, Krzyzanowski R. Phenolic acids of walnut (Juglans regia L.). Herba Polonica 57(2), 22–29 (2011).
  CASGoogle Scholar
• 47. Lafay S, Gil-Izquierdo A. Bioavailability of phenolic acids. Phytochem. Rev. 7(2), 301–311 (2007).
  Google Scholar
• 48. Russell W, Duthie G. Plant secondary metabolites and gut health: the case for phenolic acids. Proc. Nutr. Soc. 70(3), 389–396 (2011).
  Medline CASGoogle Scholar
• 49. Abotaleb M, Liskova A, Kubatka P, Büsselberg D. Therapeutic potential of plant phenolic acids in the treatment of cancer. Biomolecules 10, 221 (2020).
  Medline CASGoogle Scholar
• 50. Lana R, Silva NJA. Anticancer properties of phenolic acids in colon cancer – a review. J. Nutr. Food Sci. 06(02), 10.4172/2155-9600.1000468 (2016).
  Google Scholar
• 51. Srinivasulu C, Ramgopal M, Ramanjaneyulu G, Anuradha CM, Suresh Kumar C. Syringic acid (SA) – a review of its occurrence, biosynthesis, pharmacological and industrial importance. Biomed. Pharmacother. 108, 547–557 (2018).
  Medline CASGoogle Scholar
• 52. Kang DY, Nipin SP, Jo ES et al. The inhibitory mechanisms of tumor PD-L1 expression by natural bioactive gallic acid in non-small-cell lung cancer (NSCLC) cells. Cancers 12(3), 727 (2020).
  Medline CASGoogle Scholar
• 53. Kawada M, Ohno Y, Ri Y et al. Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice. Anticancer Drugs 12(10), 847–852 (2001).
  Medline CASGoogle Scholar
• 54. Velli SK, Sundaram J, Murugan M, Balaraman G, Thiruvengadam D. Protective effect of vanillic acid against benzo(a)pyrene induced lung cancer in Swiss albino mice. J. Biochem. Mol. Toxicol. 33(10), e22382 (2019).
  Medline CASGoogle Scholar
• 55. Yin MC, Lin CC, Wu HC, Tsao SM, Hsu CK. Apoptotic effects of protocatechuic acid in human breast, lung, liver, cervix, and prostate cancer cells: potential mechanisms of action. J. Agric. Food Chem. 57(14), 6468–6473 (2009).
  Medline CASGoogle Scholar
• 56. Tsao SM, Hsia TC, Yin MC. Protocatechuic acid inhibits lung cancer cells by modulating FAK, MAPK, and NF-κB pathways. Nutr. Cancer 66(8), 1331–1341 (2014).
  Medline CASGoogle Scholar
• 57. Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int. J. Clin. Pharmacol. Ther. Toxicol. 24(12), 651–654 (1986).
  Medline CASGoogle Scholar
• 58. Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK. Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J. Agric. Food Chem. 47(10), 4297–4300 (1999).
  Medline CASGoogle Scholar
• 59. Mehta HJ, Patel V, Sadikot RT. Curcumin and lung cancer – a review. Target. Oncol. 9(4), 295–310 (2014).
  MedlineGoogle Scholar
• 60. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23(1A), 363–398 (2003).
  Medline CASGoogle Scholar
• 61. Tsai JR, Liu PL, Chen YH et al. Curcumin inhibits non-small-cell lung cancer cells metastasis through the adiponectin/NF-κB/MMPs signaling pathway. PLOS ONE 10(12), e0144462 (2015).
  MedlineGoogle Scholar
• 62. Radhakrishna Pillai G, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett. 208(2), 163–170 (2004).
  MedlineGoogle Scholar
• 63. Tang X, Ding H, Liang M et al. Curcumin induces ferroptosis in non-small-cell lung cancer via activating autophagy. Thorac. Cancer 12(8), 1219–1230 (2021).
  Medline CASGoogle Scholar
• 64. Bourne LC, Rice-Evans C. Bioavailability of ferulic acid. Biochem. Biophys. Res. Commun. 253(2), 222–227 (1998).
  Medline CASGoogle Scholar
• 65. Bandugula VR, Prasad NR. 2-Deoxy-D-glucose and ferulic acid modulates radiation response signaling in non-small-cell lung cancer cells. Tumor Biol. 34(1), 251–259 (2013).
  Medline CASGoogle Scholar
• 66. Fong Y, Tang CC, Hu HT et al. Inhibitory effect of trans-ferulic acid on proliferation and migration of human lung cancer cells accompanied with increased endogenous reactive oxygen species and β-catenin instability. Chin. Med. 11(1), 1–13 (2016).
  MedlineGoogle Scholar
• 67. Jose Merlin JP, Venkadesh B, Hussain R, Rajan SS. Biochemical estimations of multidrug resistance (ferulic acid and paclitaxel) in non-small cells lung carcinoma cells in vitro. Biomed. Aging Pathol. 3(2), 47–50 (2013).
  Google Scholar
• 68. Ulasli SS, Celik S, Gunay E et al. Anticancer effects of thymoquinone, caffeic acid phenethyl ester and resveratrol on A549 non-small-cell lung cancer cells exposed to benzo(a)pyrene. Asian Pac. J. Cancer Prev. 14(10), 6159–6164 (2013).
  MedlineGoogle Scholar
• 69. Lin CL, Chen RF, Chen JY et al. Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-κB pathway. Int. J. Mol. Sci. 13(5), 6236–6245 (2012).
  Medline CASGoogle Scholar
• 70. Klein-Júnior LC, Campos A, Niero R, Corrêa R, Vander Heyden Y, Filho VC. Xanthones and cancer: from natural sources to mechanisms of action. Chem. Biodivers. 17(2), e1900499 (2020).
  Medline CASGoogle Scholar
• 71. Singla RK, Dubey AK, Garg A et al. Natural polyphenols: chemical classification, definition of classes, subcategories, and structures. J. AOAC Int. 102(5) 1397–1400 (2019).
  Medline CASGoogle Scholar
• 72. Zhang C, Yu G, Shen Y. The naturally occurring xanthone α-mangostin induces ROS-mediated cytotoxicity in non-small scale lung cancer cells. Saudi J. Biol. Sci. 25(6), 1090–1095 (2018).
  Medline CASGoogle Scholar
• 73. De Filippis B, Ammazzalorso A, Fantacuzzi M, Giampietro L, Maccallini C, Amoroso R. Anticancer activity of stilbene-based derivatives. ChemMedChem 12(8), 558–570 (2017).
  MedlineGoogle Scholar
• 74. Shen T, Wang XN, Lou HX. Natural stilbenes: an overview. Nat. Prod. Rep. 26(7), 916–935 (2009).
  Medline CASGoogle Scholar
• 75. Whyte L, Huang YY, Torres K, Mehta RG. Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res. 67(24), 12007–12017 (2007).
  Medline CASGoogle Scholar
• 76. Luo H, Yang A, Schulte BA, Wargovich MJ, Wang GY. Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage. PLOS ONE 8(3), e60065–e60065 (2013).
  Medline CASGoogle Scholar
• 77. Vinardell MP, Mitjans M. Lignins and their derivatives with beneficial effects on human health. Int. J. Mol. Sci. 18(6), 1219 (2017).
  MedlineGoogle Scholar
• 78. Xian H, Feng W, Zhang J. Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small-cell lung cancer. Eur. J. Pharmacol. 855, 10–19 (2019).
  Medline CASGoogle Scholar
• 79. Rajasekar N, Sivanantham A, Ravikumar V, Rajasekaran S. An overview on the role of plant-derived tannins for the treatment of lung cancer. Phytochemistry 188, 112799–112799 (2021).
  Medline CASGoogle Scholar
• 80. Sp N, Kang DY, Kim DH et al. Tannic acid inhibits non-small-cell lung cancer (NSCLC) stemness by inducing G0/G1 cell cycle arrest and intrinsic apoptosis. Anticancer Res. 40(6), 3209–3220 (2020).
  Medline CASGoogle Scholar
• 81. Pattarayan D, Sivanantham A, Krishnaswami V et al. Tannic acid attenuates TGF-β1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-β signaling in lung epithelial cells. J. Cell. Physiol. 233(3), 2513–2525 (2018). •• Overview of the significance of various polyphenols (phenolic acids, stilbenes and lignans) encapsulated in nanocarriers in lung cancer therapy.
  Medline CASGoogle Scholar
• 82. Bharadwaj P, Das SS, Beg S, Rahman M. Formulation and biological stability of nanomedicines in cancer treatment. In: Nanoformulation Strategies for Cancer Treatment. Beg SRahman MChoudhry HSouto EBAhmad F (Eds). Elsevier, Amsterdam, Netherlands, 277–289 (2021).
  Google Scholar
• 83. Vasantha Rupasinghe HP, Nair SVG, Robinson RA. Chemopreventive Properties of Fruit Phenolic Compounds and Their Possible Mode of Actions. 42, 229–266 (2014).
  Google Scholar
• 84. Ferrazzano GF, Amato I, Ingenito A, Zarrelli A, Pinto G, Pollio A. Plant polyphenols and their anti-cariogenic properties: a review. Molecules 16(2), 1486–1507 (2011).
  Medline CASGoogle Scholar
• 85. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients 2(12), 1231–1246 (2010).
  Medline CASGoogle Scholar
• 86. Mangal S, Gao W, Li T, Zhou QT. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities. Acta Pharmacol. Sin. 38(6), 782–797 (2017).
  Medline CASGoogle Scholar
• 87. Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH et al. Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective. Int. J. Nanomed. 12, 2689–2702 (2017).
  Medline CASGoogle Scholar
• 88. Das SS, Bharadwaj P, Bilal M et al. Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. Polymers (Basel) 12(6), 1397 (2020).
  Medline CASGoogle Scholar
• 89. Ernest U, Chen HY, Xu MJ et al. Anti-cancerous potential of polyphenol-loaded polymeric nanotherapeutics. Molecules 23(11), 2787 (2018).
  MedlineGoogle Scholar
• 90. Kaminskas LM, McLeod VM, Ryan GM et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J. Control. Rel. 183, 18–26 (2014).
  Medline CASGoogle Scholar
• 91. Hafez IM, Cullis PR. Roles of lipid polymorphism in intracellular delivery. Adv. Drug Deliv. Rev. 47(2-3), 139–148 (2001).
  Medline CASGoogle Scholar
• 92. Joshi N, Shirsath N, Singh A, Joshi KS, Banerjee R. Endogenous lung surfactant inspired pH responsive nanovesicle aerosols: pulmonary compatible and site-specific drug delivery in lung metastases. Sci. Rep. 4, 7085 (2014).
  MedlineGoogle Scholar
• 93. Zhu J, Liao L, Zhu L et al. Size-dependent cellular uptake efficiency, mechanism, and cytotoxicity of silica nanoparticles toward HeLa cells. Talanta 107, 408–415 (2013).
  Medline CASGoogle Scholar
• 94. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189–207 (2001).
  Medline CASGoogle Scholar
• 95. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 65(13-14), 1866–1879 (2013).
  Medline CASGoogle Scholar
• 96. Garbuzenko OB, Mainelis G, Taratula O, Minko T. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol. Med. 11(1), 44–55 (2014). •• Focus on phenolic acids (hydroxybenzoic acid)-loaded nanocarriers in lung cancer therapy.
  Medline CASGoogle Scholar
• 97. Komenek S, Luesakul U, Ekgasit S et al. Nanogold–gallate chitosan-targeted pulmonary delivery for treatment of lung cancer. AAPS PharmSciTech 18(4), 1104–1115 (2017).
  Medline CASGoogle Scholar
• 98. Sunil Gowda SN, Rajasowmiya S, Vadivel V et al. Gallic acid-coated sliver nanoparticle alters the expression of radiation-induced epithelial-mesenchymal transition in non-small lung cancer cells. Toxicol. In Vitro 52, 170–177 (2018).
  MedlineGoogle Scholar
• 99. Rosman R, Saifullah B, Maniam S, Dorniani D, Hussein MZ, Fakurazi S. Improved anticancer effect of magnetite nanocomposite formulation of gallic acid (Fe₃O₄-PEG-GA) against lung, breast and colon cancer cells. Nanomaterials (Basel) 8(2), 83 (2018).
  MedlineGoogle Scholar
• 100. Gupta N, Bhagat S, Singh M et al. Site-specific delivery of a natural chemotherapeutic agent to human lung cancer cells using biotinylated 2D rGO nanocarriers. Mater. Sci. Eng. C Mater. Biol. Appl. 112, 110884 (2020).
  Medline CASGoogle Scholar
• 101. Cordova CAS, Locatelli C, Winter E et al. Solid lipid nanoparticles improve octyl gallate antimetastatic activity and ameliorate its renal and hepatic toxic effects. Anticancer Drugs 28(9), 977–988 (2017).
  Medline CASGoogle Scholar
• 102. Huang X, Tian X, Zhang Q et al. Combined photothermal–immunotherapy via poly-tannic acid coated PLGA nanoparticles for cancer treatment. Biomater. Sci. 9(18), 6282–6294 (2021). •• Focus on phenolic acids (hydroxycinnamic acid)-loaded nanocarriers in lung cancer therapy.
  Medline CASGoogle Scholar
• 103. Lee HY, Jeong YI, Kim EJ et al. Preparation of caffeic acid phenethyl ester-incorporated nanoparticles and their biological activity. J. Pharm. Sci. 104(1), 144–154 (2015).
  Medline CASGoogle Scholar
• 104. Wang BL, Shen YM, Zhang QW et al. Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer. Int. J. Nanomed. 8, 3521–3531 (2013).
  MedlineGoogle Scholar
• 105. Yin H, Zhang H, Liu B. Superior anticancer efficacy of curcumin-loaded nanoparticles against lung cancer. Acta Biochim. Biophys. Sin. (Shanghai) 45(8), 634–640 (2013).
  Medline CASGoogle Scholar
• 106. Wang P, Zhang L, Peng H, Li Y, Xiong J, Xu Z. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small-cell lung cancer both in vitro and in vivo. Mater. Sci. Eng. C Mater. Biol. Appl. 33(8), 4802–4808 (2013).
  Medline CASGoogle Scholar
• 107. Sridhar R, Ravanan S, Venugopal JR et al. Curcumin- and natural extract-loaded nanofibres for potential treatment of lung and breast cancer: in vitro efficacy evaluation. J. Biomater. Sci. Polym. Ed. 25(10), 985–998 (2014).
  Medline CASGoogle Scholar
• 108. Teong B, Lin CY, Chang SJ et al. Enhanced anticancer activity by curcumin-loaded hydrogel nanoparticle derived aggregates on A549 lung adenocarcinoma cells. J. Mater. Sci. Mater. Med. 26(1), 5357 (2015).
  MedlineGoogle Scholar
• 109. Gu Y, Li J, Li Y et al. Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer. Int. J. Nanomed. 11, 5757–5770 (2016).
  Medline CASGoogle Scholar
• 110. Lee WH, Loo CY, Ong HX, Traini D, Young PM, Rohanizadeh R. Synthesis and characterization of inhalable flavonoid nanoparticle for lung cancer cell targeting. J. Biomed. Nanotechnol. 12(2), 371–386 (2016).
  MedlineGoogle Scholar
• 111. Ranjan AP, Mukerjee A, Gdowski A et al. Curcumin–ER prolonged subcutaneous delivery for the treatment of non-small-cell lung cancer. J. Biomed. Nanotechnol. 12(4), 679–688 (2016).
  Medline CASGoogle Scholar
• 112. Zhu WT, Liu SY, Wu L et al. Delivery of curcumin by directed self-assembled micelles enhances therapeutic treatment of non-small-cell lung cancer. Int. J. Nanomed. 12, 2621–2634 (2017).
  Medline CASGoogle Scholar
• 113. Luo CQ, Xing L, Cui PF et al. Curcumin-coordinated nanoparticles with improved stability for reactive oxygen species-responsive drug delivery in lung cancer therapy. Int. J. Nanomed. 12, 855–869 (2017).
  Medline CASGoogle Scholar
• 114. Ibrahim S, Tagami T, Kishi T, Ozeki T. Curcumin marinosomes as promising nano-drug delivery system for lung cancer. Int. J. Pharm. 540(1-2), 40–49 (2018).
  Medline CASGoogle Scholar
• 115. Khan MN, Haggag YA, Lane ME, McCarron PA, Tambuwala MM. Polymeric nano-encapsulation of curcumin enhances its anticancer activity in breast (MDA-MB231) and lung (A549) cancer cells through reduction in expression of HIF-1alpha and nuclear p65 (Rel A). Curr. Drug Deliv. 15(2), 286–295 (2018).
  Medline CASGoogle Scholar
• 116. Jiang K, Shen M, Xu W. Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation. Int. J. Nanomed. 13, 2561–2569 (2018).
  Medline CASGoogle Scholar
• 117. Hong Y, Che S, Hui B, Wang X, Zhang X, Ma H. Combination therapy of lung cancer using layer-by-layer cisplatin prodrug and curcumin co-encapsulated nanomedicine. Drug Des. Devel. Ther. 14, 2263–2274 (2020).
  Medline CASGoogle Scholar
• 118. Mardani R, Hamblin MR, Taghizadeh M et al. Nanomicellar-curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of melanoma lung metastasis. Pathol. Res. Pract. 216(9), 153082 (2020).
  Medline CASGoogle Scholar
• 119. Zhu X, Yu Z, Feng L et al. Chitosan-based nanoparticle co-delivery of docetaxel and curcumin ameliorates anti-tumor chemoimmunotherapy in lung cancer. Carbohydr. Polym. 268, 118237 (2021).
  Medline CASGoogle Scholar
• 120. Merlin JPJ, Rajendra Prasad N, Shibli SMA, Sebeela M. Ferulic acid loaded Poly-d,l-lactide-co-glycolide nanoparticles: systematic study of particle size, drug encapsulation efficiency and anticancer effect in non-small-cell lung carcinoma cell line in vitro. Biomed. Preventive Nutr. 2(1), 69–76 (2012).
  Google Scholar
• 121. Hassanzadeh P, Arbabi E, Rostami F, Atyabi F, Dinarvand R. Aerosol delivery of ferulic acid-loaded nanostructured lipid carriers: a promising treatment approach against the respiratory disorders. Physiol. Pharmacol. 21(4), 331–342 (2017). •• Focus on stilbenes/lignans-loaded nanocarriers for lung cancer therapy.
  Google Scholar
• 122. Hu J, Chen LJ, Liu L et al. Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic anti-tumor efficacy without increasing toxicity. Exp. Mol. Med. 40(6), 617–628 (2008).
  Medline CASGoogle Scholar
• 123. Wen J, Fu AF, Chen LJ et al. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int. J. Cancer 124(11), 2709–2718 (2009).
  Medline CASGoogle Scholar
• 124. Yang J, Pei H, Luo H et al. Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways. Oncotarget 8(1), 915–932 (2017).
  MedlineGoogle Scholar
• 125. Yang J, Wu W, Wen J et al. Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells. Biomaterials 141, 188–198 (2017).
  Medline CASGoogle Scholar
• 126. Ong CP, Lee WL, Tang YQ, Yap WH. Honokiol: a review of its anticancer potential and mechanisms. Cancers (Basel) 12(1), 48 (2020).
  CASGoogle Scholar
• 127. Jiang QQ, Fan LY, Yang GL et al. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC Cancer 8, 242 (2008).
  MedlineGoogle Scholar
• 128. Li X, Guo Q, Zheng X et al. Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery. Drug Deliv. 16(3), 160–166 (2009).
  Medline CASGoogle Scholar
• 129. Gong C, Wei X, Wang X et al. Biodegradable self-assembled PEG–PCL–PEG micelles for hydrophobic honokiol delivery: I. Preparation and characterization. Nanotechnology 21(21), 215103 (2010).
  MedlineGoogle Scholar
• 130. Jin X, Yang Q, Cai N, Zhang Z. A cocktail of betulinic acid, parthenolide, honokiol and ginsenoside Rh2 in liposome systems for lung cancer treatment. Nanomedicine (Lond.) 15(1), 41–54 (2020).
  CASGoogle Scholar
• 131. Song Z, Shi Y, Han Q, Dai G. Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid–polymer hybrid nanoparticles. Biomed. Pharmacother. 105, 18–26 (2018).
  Medline CASGoogle Scholar
• 132. Wang XX, Li YB, Yao HJ et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol–distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 32(24), 5673–5687 (2011).
  Medline CASGoogle Scholar
• 133. Karthikeyan S, Rajendra Prasad N, Ganamani A, Balamurugan E. Anticancer activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small-cell lung cancer cells. Biomed. Preventive Nutr. 3(1), 64–73 (2013).
  Google Scholar
• 134. Karthikeyan S, Hoti SL, Prasad NR. Resveratrol loaded gelatin nanoparticles synergistically inhibits cell cycle progression and constitutive NF-kappaB activation, and induces apoptosis in non-small-cell lung cancer cells. Biomed. Pharmacother. 70, 274–282 (2015).
  Medline CASGoogle Scholar
• 135. Kim JH, Park EY, Ha HK et al. Resveratrol-loaded nanoparticles induce antioxidant activity against oxidative stress. Asian-Australas. J. Anim. Sci. 29(2), 288–298 (2016).
  Medline CASGoogle Scholar
• 136. Zhao QS, Hu LL, Wang ZD, Li ZP, Wang AW, Liu J. Resveratrol-loaded folic acid-grafted dextran stearate submicron particles exhibits enhanced anti-tumor efficacy in non-small-cell lung cancers. Mater. Sci. Eng. C Mater. Biol. Appl. 72, 185–191 (2017).
  Medline CASGoogle Scholar
• 137. Abdelaziz HM, Elzoghby AO, Helmy MW, Samaha MW, Fang JY, Freag MS. Liquid crystalline assembly for potential combinatorial chemo-herbal drug delivery to lung cancer cells. Int. J. Nanomed. 14, 499–517 (2019).
  Medline CASGoogle Scholar
• 138. Abdelaziz HM, Elzoghby AO, Helmy MW et al. Inhalable lactoferrin/chondroitin-functionalized monoolein nanocomposites for localized lung cancer targeting. ACS Biomater. Sci Eng. 6(2), 1030–1042 (2020).
  Medline CASGoogle Scholar
• 139. Zhang L, Zhu K, Zeng H et al. Resveratrol solid lipid nanoparticles to trigger credible inhibition of doxorubicin cardiotoxicity. Int. J. Nanomed. 14, 6061–6071 (2019).
  Medline CASGoogle Scholar